Standard BioTools opened higher at $0.65, compared with its previous close of $0.64. In the last trading session, the stock traded between $0.64 and $0.68. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Standard BioTools is now worth
$ 17.29
Resulting in a loss of
$ 82.71 (82.71%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$0.01 (+2.18%)
Day High
$0.68
Day Low
$0.64
Day Open
$0.65
Prev Close
$0.64
Volume
3,19,195
1W Return
6.48%
1M Return
-0.30%
3M Return
-16.09%
6M Return
-33.64%
1Y Return
-44.79%
Market Cap ($ Mn)
259
PE Ratio
-
PB Ratio
0.46
PEG Ratio
-
ROE
-13.52%
ROCE
-21.87%
EPS (TTM)
$0.03
1 Week
6.48%
1 Month
-0.30%
3 Months
-16.09%
6 Months
-33.64%
9 Months
-44.79%
Standard BioTools agrees to sell Microfluidics business to ARCHIMED
Standard BioTools entered a definitive agreement to sell its Microfluidics business to ARCHIMED. The transaction is expected to close in approximately 30 days subject to customary conditions. CEO Michael Egholm cited ARCHIMED’s healthcare expertise and resources as key drivers for the sale. The announcement coincides with other pending transactions involving Treeline Biosciences and Element Biosystems.
1mo agoStandard BioTools sells Mass Cytometry unit to Element for $5.5M
Standard BioTools sold its Mass Cytometry business to Element Biosystems for $5.5 million in cash. The deal replaces a prior agreement with Multiplex Bio that required a $10 million working capital loan. Net cash position for the pending Treeline merger improves by approximately $15 million due to the new terms. Element Biosystems is an acquisition vehicle formed by GMT Venture Partners, LLC. Closing is expected by the end of 2026, concurrent with the Treeline Biosciences merger.
1mo agoStandard BioTools sells Mass Cytometry unit to Multiplex Bio for up to $10M
Standard BioTools Inc. agreed to sell its Mass Cytometry business to Multiplex Bio for up to $10 million and received approximately $30 million from Illumina Inc. to settle earnout and royalty obligations. These transactions streamline operations ahead of the company's merger with Treeline Biosciences Inc., which received FTC clearance.
3mo agoStandard BioTools files S-4 for Treeline merger
Standard BioTools Inc. filed an S-4 registration statement for its all-stock merger with Treeline Biosciences, Inc., expected to close in the second half of 2026. The combined company projects over $900 million in pro-forma cash to fund operations into 2029. Treeline reported an 84% overall response rate for its TLN-121 therapy in a Phase 1 trial for relapsed or refractory lymphomas.
3mo agoHalper Sadeh investigates Standard BioTools merger fairness
Halper Sadeh LLC is investigating the merger of Standard BioTools Inc. and Treeline Biosciences over concerns regarding fair pricing and fiduciary duties. Standard BioTools shareholders are expected to own 16% of the combined entity. The firm may seek increased consideration or additional disclosures for shareholders.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Standard BioTools is now worth
$ 17.29
Resulting in a loss of
$ 82.71 (82.71%)
Note: Past profits do not guarantee future returns.
